NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that its Asia Pacific strategic partner Lotus Pharmaceutical Co. Ltd (1975.TW) identified enrollment completion of the NRx clinical trial in bipolar depression as a material event in is February 7 financial filing.[1] Lotus provides the Asia Pacific component of NRx’s global partnership with Alvogen, Inc.
Lotus reported in the accompanying press release that “Lotus Pharmaceutical’s strategic partner, NRX Pharmaceuticals, has achieved a significant milestone by completing enrollment for its phase 2b/3 trial of NRX-101 in suicidal treatment-resistant bipolar depression. The readout for this trial is anticipated in Q2 of this year.”
“We at NRx are honored that Lotus has focused its resources on helping us advance NRX-101 for the benefit of patients in the Asia Pacific region. As reported by the World Health Organization, suicidal depression is a significant public health crisis in Pacific rim countries[2], just as it is in the US,” said Stephen Willard, Chief Executive Officer of NRx Pharmaceuticals. “We recently held very productive meetings at the JP Morgan conference in San Francisco; we share a mutual commitment to bringing a lifesaving treatment to patients who have been excluded from the clinical trials of all known antidepressants and whose only approved treatment today is electroshock therapy.”
NRx anticipates further updates regarding its global partnerships in the coming days.
